Head-to-head evidence
BAT1706 vs HD204
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline
BAT1706 · Avzivi
Marketed by Bio-Thera Solutions
NCT03329911 · Phase 3 · completed
The trial was randomized, double-blind, and actively controlled, with 651 participants, and used a clinical tumor-response endpoint assessed by RECIST 1.1. However, the week-18 primary endpoint comparison is unclear because only response counts are posted and no statistical analysis is reported.
HD204
Developed by Prestige Biopharma Limited
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT1706's landscape · HD204's landscape